|
1
|
Universal definition of myocardial infarction.
|
Circulation
|
2007
|
11.69
|
|
2
|
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
|
JAMA
|
2004
|
9.74
|
|
3
|
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
|
N Engl J Med
|
2004
|
9.13
|
|
4
|
Universal definition of myocardial infarction.
|
Eur Heart J
|
2007
|
9.04
|
|
5
|
Universal definition of myocardial infarction.
|
J Am Coll Cardiol
|
2007
|
8.68
|
|
6
|
Third universal definition of myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
8.59
|
|
7
|
Third universal definition of myocardial infarction.
|
Circulation
|
2012
|
8.47
|
|
8
|
Third universal definition of myocardial infarction.
|
Eur Heart J
|
2012
|
7.98
|
|
9
|
Bivalirudin for patients with acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.49
|
|
10
|
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
|
Lancet
|
2010
|
5.30
|
|
11
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
|
N Engl J Med
|
2006
|
5.07
|
|
12
|
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
|
N Engl J Med
|
2012
|
4.49
|
|
13
|
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
|
N Engl J Med
|
2013
|
4.16
|
|
14
|
Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy.
|
Circulation
|
2010
|
3.95
|
|
15
|
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
|
N Engl J Med
|
2006
|
3.56
|
|
16
|
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
|
Circulation
|
2002
|
3.48
|
|
17
|
Intravenous platelet blockade with cangrelor during PCI.
|
N Engl J Med
|
2009
|
3.31
|
|
18
|
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
|
N Engl J Med
|
2011
|
3.20
|
|
19
|
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
|
JAMA
|
2007
|
3.07
|
|
20
|
Darapladib for preventing ischemic events in stable coronary heart disease.
|
N Engl J Med
|
2014
|
2.90
|
|
21
|
Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial.
|
Circulation
|
2010
|
2.88
|
|
22
|
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
|
Lancet
|
2007
|
2.67
|
|
23
|
Platelet inhibition with cangrelor in patients undergoing PCI.
|
N Engl J Med
|
2009
|
2.52
|
|
24
|
Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
2.47
|
|
25
|
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
|
JAMA
|
2004
|
2.46
|
|
26
|
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study.
|
Lancet
|
2003
|
2.45
|
|
27
|
Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
|
Circulation
|
2007
|
2.42
|
|
28
|
Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.
|
JAMA
|
2006
|
2.35
|
|
29
|
Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
|
Circulation
|
2007
|
2.30
|
|
30
|
Design and methodology of the Occluded Artery Trial (OAT).
|
Am Heart J
|
2005
|
2.26
|
|
31
|
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
|
Lancet
|
2013
|
2.22
|
|
32
|
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
|
JAMA
|
2012
|
2.22
|
|
33
|
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
|
Circulation
|
2008
|
2.19
|
|
34
|
Sex differences in mortality following acute coronary syndromes.
|
JAMA
|
2009
|
2.17
|
|
35
|
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.
|
JAMA
|
2005
|
2.17
|
|
36
|
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.
|
J Am Coll Cardiol
|
2007
|
2.14
|
|
37
|
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
|
Am J Med
|
2002
|
2.09
|
|
38
|
Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.
|
Eur Heart J
|
2005
|
2.08
|
|
39
|
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
|
Am Heart J
|
2008
|
2.04
|
|
40
|
Comparison of a 3-hour versus a 6-hour sampling-protocol using high-sensitivity cardiac troponin T for rule-out and rule-in of non-STEMI in an unselected emergency department population.
|
Int J Cardiol
|
2012
|
2.02
|
|
41
|
Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?
|
J Am Coll Cardiol
|
2011
|
2.00
|
|
42
|
Depression and cardiovascular morbidity and mortality: cause or consequence?
|
Eur Heart J
|
2003
|
2.00
|
|
43
|
Improving cardiovascular risk assessment.
|
N Z Med J
|
2011
|
1.96
|
|
44
|
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes.
|
Int J Cardiol
|
2013
|
1.95
|
|
45
|
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
1.88
|
|
46
|
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.86
|
|
47
|
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
|
JAMA
|
2007
|
1.84
|
|
48
|
2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006.
|
Heart Lung Circ
|
2011
|
1.71
|
|
49
|
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2009
|
1.70
|
|
50
|
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Circulation
|
2007
|
1.67
|
|
51
|
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study.
|
JACC Cardiovasc Interv
|
2008
|
1.63
|
|
52
|
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone.
|
Am J Cardiol
|
2002
|
1.60
|
|
53
|
Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2.
|
Lancet
|
2006
|
1.59
|
|
54
|
Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction.
|
J Am Coll Cardiol
|
2005
|
1.58
|
|
55
|
Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes.
|
J Am Coll Cardiol
|
2005
|
1.58
|
|
56
|
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study.
|
Eur Heart J
|
2008
|
1.57
|
|
57
|
aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction.
|
Eur Heart J
|
2010
|
1.57
|
|
58
|
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
|
JACC Cardiovasc Interv
|
2009
|
1.56
|
|
59
|
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
|
Eur Heart J
|
2013
|
1.56
|
|
60
|
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
|
Eur Heart J
|
2004
|
1.55
|
|
61
|
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
|
J Am Coll Cardiol
|
2003
|
1.54
|
|
62
|
Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?
|
JAMA
|
2005
|
1.54
|
|
63
|
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
|
Eur Heart J
|
2013
|
1.53
|
|
64
|
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
|
JAMA
|
2005
|
1.52
|
|
65
|
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction.
|
Crit Care Med
|
2011
|
1.50
|
|
66
|
Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes.
|
JACC Cardiovasc Interv
|
2012
|
1.50
|
|
67
|
Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis.
|
Eur Heart J
|
2010
|
1.49
|
|
68
|
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT).
|
Eur Heart J
|
2009
|
1.48
|
|
69
|
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention.
|
J Interv Cardiol
|
2009
|
1.47
|
|
70
|
Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.
|
Heart Lung Circ
|
2011
|
1.47
|
|
71
|
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial.
|
Eur Heart J
|
2008
|
1.47
|
|
72
|
Lessons learned from a clinical trial.
|
Circulation
|
2004
|
1.46
|
|
73
|
Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
|
N Z Med J
|
2008
|
1.46
|
|
74
|
A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry.
|
Am Heart J
|
2010
|
1.46
|
|
75
|
A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial.
|
Heart
|
2013
|
1.45
|
|
76
|
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
|
Int J Cardiol
|
2009
|
1.45
|
|
77
|
Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial.
|
J Am Coll Cardiol
|
2003
|
1.44
|
|
78
|
Public sensationalism and clinical trials: how to address the challenges of science?
|
Am J Med
|
2010
|
1.42
|
|
79
|
Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin.
|
J Hypertens
|
2002
|
1.42
|
|
80
|
The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial.
|
Heart
|
2013
|
1.41
|
|
81
|
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
|
Heart Rhythm
|
2006
|
1.41
|
|
82
|
A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction.
|
Am Heart J
|
2003
|
1.40
|
|
83
|
Clinical implications of the new definition of myocardial infarction.
|
Heart
|
2004
|
1.39
|
|
84
|
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis.
|
Circulation
|
2003
|
1.38
|
|
85
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
86
|
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
|
Circulation
|
2004
|
1.27
|
|
87
|
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
|
Am Heart J
|
2011
|
1.23
|
|
88
|
The universal definition of myocardial infarction: a consensus document: ischaemic heart disease.
|
Heart
|
2008
|
1.21
|
|
89
|
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial.
|
Eur Heart J
|
2009
|
1.21
|
|
90
|
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
|
Am Heart J
|
2004
|
1.19
|
|
91
|
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.17
|
|
92
|
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.16
|
|
93
|
Third universal definition of myocardial infarction.
|
Glob Heart
|
2012
|
1.14
|
|
94
|
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
|
Circulation
|
2009
|
1.14
|
|
95
|
Third universal definition of myocardial infarction.
|
Nat Rev Cardiol
|
2012
|
1.12
|
|
96
|
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.
|
Int J Cardiol
|
2012
|
1.12
|
|
97
|
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.
|
Am Heart J
|
2006
|
1.10
|
|
98
|
Effect of six months' exercise training on C-reactive protein levels in healthy elderly subjects.
|
J Am Coll Cardiol
|
2004
|
1.10
|
|
99
|
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
|
Eur Heart J
|
2010
|
1.08
|
|
100
|
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
|
Am Heart J
|
2010
|
1.07
|
|
101
|
Risk stratification of patients with acute anterior myocardial infarction and right bundle-branch block: importance of QRS duration and early ST-segment resolution after fibrinolytic therapy.
|
Circulation
|
2006
|
1.06
|
|
102
|
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
|
Am Heart J
|
2012
|
1.05
|
|
103
|
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction.
|
Am J Med
|
2006
|
1.04
|
|
104
|
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
|
Eur Heart J
|
2009
|
1.03
|
|
105
|
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
|
JACC Cardiovasc Interv
|
2008
|
1.02
|
|
106
|
Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
|
Am J Cardiol
|
2009
|
1.02
|
|
107
|
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
|
Eur J Heart Fail
|
2003
|
1.02
|
|
108
|
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.
|
Eur Heart J
|
2009
|
1.01
|
|
109
|
Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction.
|
Am J Cardiol
|
2004
|
1.01
|
|
110
|
Diagnosis of MI after CABG with high-sensitivity troponin T and new ECG or echocardiogram changes: relationship with mortality and validation of the universal definition of MI.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
1.00
|
|
111
|
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
|
Am Heart J
|
2003
|
0.99
|
|
112
|
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2004
|
0.98
|
|
113
|
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.
|
Card Electrophysiol Rev
|
2003
|
0.98
|
|
114
|
International variation in the use of evidence-based medicines for acute coronary syndromes.
|
Eur Heart J
|
2003
|
0.98
|
|
115
|
The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction.
|
Eur Heart J
|
2011
|
0.97
|
|
116
|
Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).
|
Am Heart J
|
2005
|
0.97
|
|
117
|
Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.
|
Circulation
|
2011
|
0.96
|
|
118
|
Prognostic value of lead V1 ST elevation during acute inferior myocardial infarction.
|
Circulation
|
2010
|
0.96
|
|
119
|
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.95
|
|
120
|
International variation in invasive care of the elderly with acute coronary syndromes.
|
Eur Heart J
|
2006
|
0.95
|
|
121
|
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention.
|
Int J Cardiol
|
2010
|
0.95
|
|
122
|
Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis.
|
Am J Cardiol
|
2003
|
0.94
|
|
123
|
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
|
Circulation
|
2002
|
0.94
|
|
124
|
Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery.
|
Ann Thorac Surg
|
2004
|
0.94
|
|
125
|
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography.
|
Am Heart J
|
2009
|
0.93
|
|
126
|
Evolution of the definition of myocardial infarction: what are the implications of a new universal definition?
|
Heart
|
2008
|
0.93
|
|
127
|
Cardiovascular disease on a global scale: defining the path forward for research and practice.
|
Eur Heart J
|
2007
|
0.92
|
|
128
|
Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks.
|
J Am Coll Cardiol
|
2005
|
0.92
|
|
129
|
Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.
|
Circulation
|
2003
|
0.92
|
|
130
|
Drug insight: Statin use in the elderly.
|
Nat Clin Pract Cardiovasc Med
|
2006
|
0.92
|
|
131
|
A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial.
|
Circ Cardiovasc Interv
|
2010
|
0.91
|
|
132
|
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries.
|
Am Heart J
|
2002
|
0.91
|
|
133
|
Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
|
Am Heart J
|
2011
|
0.90
|
|
134
|
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
|
J Am Coll Cardiol
|
2006
|
0.90
|
|
135
|
Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2009
|
0.90
|
|
136
|
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
|
Am Heart J
|
2002
|
0.90
|
|
137
|
Diagnostic application of the universal definition of myocardial infarction in the intensive care unit.
|
Curr Opin Crit Care
|
2008
|
0.89
|
|
138
|
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction.
|
Eur Heart J
|
2006
|
0.89
|
|
139
|
Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial.
|
Eur Heart J
|
2006
|
0.89
|
|
140
|
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial.
|
Heart
|
2010
|
0.89
|
|
141
|
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
|
Catheter Cardiovasc Interv
|
2007
|
0.89
|
|
142
|
White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
|
Circulation
|
2005
|
0.88
|
|
143
|
The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis.
|
Curr Atheroscler Rep
|
2011
|
0.88
|
|
144
|
Statin use and sex-specific stroke outcomes in patients with vascular disease.
|
Stroke
|
2006
|
0.88
|
|
145
|
Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk.
|
Am Heart J
|
2006
|
0.87
|
|
146
|
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
|
JAMA
|
2002
|
0.87
|
|
147
|
Things ain't what they used to be: impact of a new definition of myocardial infarction.
|
Am Heart J
|
2002
|
0.87
|
|
148
|
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
|
Ann Intern Med
|
2013
|
0.86
|
|
149
|
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
|
JACC Cardiovasc Interv
|
2009
|
0.86
|
|
150
|
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
|
Am Heart J
|
2002
|
0.86
|
|
151
|
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis.
|
Am J Cardiol
|
2011
|
0.85
|
|
152
|
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
|
Int J Cardiol
|
2008
|
0.85
|
|
153
|
Preventive angioplasty in myocardial infarction.
|
N Engl J Med
|
2014
|
0.85
|
|
154
|
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial.
|
J Thromb Thrombolysis
|
2011
|
0.85
|
|
155
|
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.
|
Eur Heart J
|
2008
|
0.85
|
|
156
|
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
|
Circulation
|
2013
|
0.85
|
|
157
|
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
|
J Am Coll Cardiol
|
2012
|
0.85
|
|
158
|
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.
|
J Am Coll Cardiol
|
2013
|
0.84
|
|
159
|
The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.
|
Am Heart J
|
2005
|
0.84
|
|
160
|
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2005
|
0.84
|
|
161
|
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.
|
Am Heart J
|
2005
|
0.84
|
|
162
|
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.
|
J Am Coll Cardiol
|
2002
|
0.84
|
|
163
|
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
|
Eur Heart J
|
2008
|
0.83
|
|
164
|
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2008
|
0.83
|
|
165
|
Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
|
Arterioscler Thromb Vasc Biol
|
2013
|
0.83
|
|
166
|
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
|
Circulation
|
2007
|
0.83
|
|
167
|
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
|
J Thromb Thrombolysis
|
2003
|
0.83
|
|
168
|
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients.
|
Eur Heart J Acute Cardiovasc Care
|
2013
|
0.83
|
|
169
|
The prequel: defining prognostically important criteria in the periprocedural PCI troponin saga.
|
Circ Cardiovasc Interv
|
2012
|
0.83
|
|
170
|
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy.
|
Am J Med
|
2011
|
0.82
|
|
171
|
Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial.
|
Circ Cardiovasc Interv
|
2010
|
0.82
|
|
172
|
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
|
J Gen Intern Med
|
2008
|
0.82
|
|
173
|
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
|
Arch Intern Med
|
2007
|
0.82
|
|
174
|
Withdrawal of statins in patients with acute coronary syndromes.
|
Circulation
|
2003
|
0.82
|
|
175
|
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
|
Am J Cardiol
|
2005
|
0.82
|
|
176
|
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
|
Am J Cardiol
|
2008
|
0.81
|
|
177
|
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes.
|
Am J Cardiol
|
2007
|
0.81
|
|
178
|
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.
|
Am Heart J
|
2010
|
0.81
|
|
179
|
The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?
|
Am Heart J
|
2013
|
0.81
|
|
180
|
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.
|
Am J Cardiol
|
2003
|
0.81
|
|
181
|
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
|
Am J Med
|
2010
|
0.81
|
|
182
|
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
|
Catheter Cardiovasc Interv
|
2010
|
0.81
|
|
183
|
Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.
|
Catheter Cardiovasc Interv
|
2009
|
0.81
|
|
184
|
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict.
|
Am Heart J
|
2008
|
0.80
|
|
185
|
Trans-fatty acids in New Zealand patients with coronary artery disease.
|
Eur J Cardiovasc Prev Rehabil
|
2011
|
0.80
|
|
186
|
Value of community-derived risk models for stratifying patients with non-ST elevation acute coronary syndromes.
|
Eur Heart J
|
2005
|
0.80
|
|
187
|
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock.
|
Am J Cardiol
|
2007
|
0.80
|
|
188
|
Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes.
|
J Am Coll Cardiol
|
2003
|
0.80
|
|
189
|
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
|
J Thromb Thrombolysis
|
2011
|
0.79
|
|
190
|
Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction.
|
Am Heart J
|
2002
|
0.79
|
|
191
|
Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction.
|
Am J Cardiol
|
2002
|
0.79
|
|
192
|
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
|
J Thromb Thrombolysis
|
2015
|
0.79
|
|
193
|
Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation.
|
Am J Cardiol
|
2003
|
0.79
|
|
194
|
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis.
|
J Am Coll Cardiol
|
2011
|
0.79
|
|
195
|
A case of cardiogenic shock caused by capecitabine treatment.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.79
|
|
196
|
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
|
Am J Cardiol
|
2004
|
0.79
|
|
197
|
Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction.
|
World J Cardiol
|
2010
|
0.79
|
|
198
|
Prosthetic heart valves and pregnancy.
|
Circulation
|
2003
|
0.79
|
|
199
|
Implications of the universal definition of myocardial infarction.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.79
|
|
200
|
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
|
Am Heart J
|
2006
|
0.79
|
|
201
|
Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in women.
|
Prev Cardiol
|
2007
|
0.79
|
|
202
|
A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement.
|
Clin Ther
|
2002
|
0.78
|
|
203
|
Prospective evaluation of a chest pain pathway at Green Lane Hospital.
|
N Z Med J
|
2002
|
0.78
|
|
204
|
Comparison of late results of percutaneous coronary intervention among stable patients ≤65 versus >65 years of age with an occluded infarct related artery (from the Occluded Artery Trial).
|
Am J Cardiol
|
2011
|
0.78
|
|
205
|
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
|
Am Heart J
|
2004
|
0.78
|
|
206
|
Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
|
Med J Aust
|
2002
|
0.78
|
|
207
|
Carvedilol: use in chronic heart failure.
|
Expert Rev Cardiovasc Ther
|
2007
|
0.78
|
|
208
|
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
Am Heart J
|
2006
|
0.77
|
|
209
|
Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction.
|
Am Heart J
|
2003
|
0.77
|
|
210
|
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial.
|
Am Heart J
|
2013
|
0.77
|
|
211
|
Antithrombotic therapy in ST-segment elevation myocardial infarction.
|
Expert Opin Pharmacother
|
2011
|
0.77
|
|
212
|
Restrictive physiology in cardiogenic shock: observations from echocardiography.
|
Am Heart J
|
2006
|
0.77
|
|
213
|
Systems of care: need for hub-and-spoke systems for both primary and systematic percutaneous coronary intervention after fibrinolysis.
|
Circulation
|
2008
|
0.77
|
|
214
|
Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase.
|
Am Heart J
|
2003
|
0.77
|
|
215
|
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction.
|
Eur Heart J
|
2009
|
0.77
|
|
216
|
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial.
|
J Am Coll Cardiol
|
2016
|
0.77
|
|
217
|
Letter by Mehran et al regarding article, "Bleeding academic research consortium consensus report: the food and drug administration perspective".
|
Circulation
|
2012
|
0.77
|
|
218
|
Effects of dietary factors on lipoprotein-associated phospholipase A(2) (Lp-PLA (2)).
|
Curr Atheroscler Rep
|
2011
|
0.77
|
|
219
|
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
|
Am Heart J
|
2011
|
0.77
|
|
220
|
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
|
Eur J Cardiovasc Prev Rehabil
|
2011
|
0.76
|
|
221
|
Patients with circumflex occlusions miss out on reperfusion: how to recognize and manage them.
|
Curr Opin Cardiol
|
2012
|
0.76
|
|
222
|
Higher sensitivity troponin levels in the community: what do they mean and how will the diagnosis of myocardial infarction be made?
|
Am Heart J
|
2010
|
0.76
|
|
223
|
Systems of care: need for hub and spoke systems of care for patients with myocardial infarction. A call for action.
|
N Z Med J
|
2010
|
0.76
|
|
224
|
Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial.
|
Cardiol J
|
2013
|
0.76
|
|
225
|
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
|
Am J Cardiol
|
2003
|
0.75
|
|
226
|
Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the STICH trial.
|
Eur J Heart Fail
|
2015
|
0.75
|
|
227
|
Response to letters regarding article, “Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy”.
|
Circulation
|
2011
|
0.75
|
|
228
|
Myocardial infarction: why can't we get the diagnosis right?
|
Eur Heart J
|
2003
|
0.75
|
|
229
|
Response to 'lifetime cardiovascular risk' letter.
|
N Z Med J
|
2011
|
0.75
|
|
230
|
Should bivalirudin be the anticoagulant of choice for percutaneous coronary intervention?
|
Nat Clin Pract Cardiovasc Med
|
2005
|
0.75
|
|
231
|
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium?
|
J Am Coll Cardiol
|
2014
|
0.75
|
|
232
|
Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin.
|
Am Heart J
|
2002
|
0.75
|
|
233
|
Magnetic resonance imaging and troponin elevation following percutaneous coronary intervention: new insights into myocyte necrosis and scar formation.
|
JACC Cardiovasc Interv
|
2010
|
0.75
|
|
234
|
Cardiogenic shock without flow-limiting angiographic coronary artery disease: (from the Should We Emergently Revascularize Occluded Coronary Arteries for Cardiogenic Shock Trial and Registry).
|
Am J Cardiol
|
2009
|
0.75
|
|
235
|
Reducing the lifetime cardiovascular risk of New Zealanders.
|
N Z Med J
|
2007
|
0.75
|
|
236
|
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
|
Am J Cardiovasc Drugs
|
2004
|
0.75
|
|
237
|
Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial.
|
Am J Clin Nutr
|
2005
|
0.75
|
|
238
|
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
|
Am Heart J
|
2007
|
0.75
|
|
239
|
Cardiogenic shock: predictors of outcome based on right and left ventricular size and function at presentation.
|
Coron Artery Dis
|
2005
|
0.75
|
|
240
|
Towards a new order in cardiovascular medicine: re-engineering through global collaboration.
|
Eur Heart J
|
2010
|
0.75
|
|
241
|
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials.
|
Am Heart J
|
2007
|
0.75
|
|
242
|
Elderly patients should not be denied fibrinolytic therapy.
|
Nat Clin Pract Cardiovasc Med
|
2007
|
0.75
|
|
243
|
Prognostic significance of coronary thrombus in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
JACC Cardiovasc Interv
|
2011
|
0.75
|
|
244
|
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials.
|
Eur Heart J
|
2004
|
0.75
|
|
245
|
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.
|
EuroIntervention
|
2017
|
0.75
|
|
246
|
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial.
|
Eur Heart J
|
2005
|
0.75
|
|
247
|
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study.
|
Thromb Haemost
|
2017
|
0.75
|
|
248
|
Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
249
|
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
|
Coron Artery Dis
|
2013
|
0.75
|
|
250
|
Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?
|
Curr Opin Cardiol
|
2011
|
0.75
|
|
251
|
High-sensitivity troponin level pre-catheterization predicts adverse cardiovascular outcomes after primary angioplasty for ST-elevation myocardial infarction.
|
Eur Heart J Acute Cardiovasc Care
|
2014
|
0.75
|
|
252
|
Heart, lung and circulation: flagship or millstone?
|
Heart Lung Circ
|
2004
|
0.75
|
|
253
|
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Am Heart J
|
2006
|
0.75
|
|
254
|
Myocardial infarction following sclerotherapy in a patient with a patent foramen ovale.
|
N Z Med J
|
2012
|
0.75
|
|
255
|
Increased myocardial ischemia after food is not explained by endothelial dysfunction.
|
Am Heart J
|
2002
|
0.75
|
|
256
|
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb.
|
Eur Heart J
|
2008
|
0.75
|
|
257
|
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
|
Circ Cardiovasc Qual Outcomes
|
2011
|
0.75
|
|
258
|
ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
|
Expert Rev Cardiovasc Ther
|
2007
|
0.75
|
|
259
|
Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques.
|
Am J Cardiol
|
2006
|
0.75
|
|
260
|
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings.
|
J Am Coll Cardiol
|
2016
|
0.75
|
|
261
|
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy.
|
Am J Cardiol
|
2005
|
0.75
|
|
262
|
Society's expectation of the role of the doctor in New Zealand: results of a national survey.
|
N Z Med J
|
2011
|
0.75
|
|
263
|
Cardiogenic shock from left ventricular dysfunction complicating an acute ST-elevation myocardial infarction.
|
Am Heart Hosp J
|
2009
|
0.75
|
|
264
|
Rivaroxaban for the treatment of acute coronary syndromes.
|
Expert Opin Pharmacother
|
2013
|
0.75
|
|
265
|
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
|
Int J Cardiol
|
2012
|
0.75
|
|
266
|
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
267
|
Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
|
Am J Cardiovasc Drugs
|
2007
|
0.75
|
|
268
|
The HERO-2 ECG sub-studies in patients with ST elevation myocardial infarction: implications for clinical practice.
|
Int J Cardiol
|
2013
|
0.75
|
|
269
|
Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2009
|
0.75
|
|
270
|
Postmenopausal hormone use in women with acute coronary syndromes.
|
J Womens Health (Larchmt)
|
2004
|
0.75
|
|
271
|
[Universal definition of the myocardial infarction].
|
Kardiol Pol
|
2008
|
0.75
|
|
272
|
Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).
|
Am J Cardiol
|
2010
|
0.75
|
|
273
|
Facilitated percutaneous coronary intervention: is this strategy ready for implementation?
|
Curr Cardiol Rep
|
2005
|
0.75
|